Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Kletting

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Nuklearmedizin. Nuclear Medicine|November 26, 2016
Treatment planning in PRRT based on simulated PET data and a PBPK model. Determination of accuracy using a PET noise modelDeni Hardiansyah, Wei Guo, Ali Asgar Attarwala, et al.
EJNMMI Research|March 27, 2016
Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling scheduleChristian Maaß, Jan Philipp Sachs, Deni Hardiansyah, et al.
Medical Physics|August 10, 2013
A fast method for rescaling voxel S values for arbitrary voxel sizes in targeted radionuclide therapy from a single Monte Carlo calculationMaría Fernández, Heribert Hänscheid, Thibault Mauxion, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 19, 2015
Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE TherapyPeter Kletting, Thomas Kull, Christian Maaß, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2010
Radioimmunotherapy with anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic modelPeter Kletting, Thomas Kull, Donald Bunjes, et al.
Scientific Reports|December 29, 2019
The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK modelNusrat J Begum, Gerhard Glatting, Hans-Jürgen Wester, et al.
Pharmaceutics|December 28, 2021
A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in MiceNouran R R Zaid, Peter Kletting, Gordon Winter, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 19, 2015
The role of patient-based treatment planning in peptide receptor radionuclide therapyDeni Hardiansyah, Christian Maass, Ali Asgar Attarwala, et al.
Zeitschrift Fur Medizinische Physik|March 21, 2015
The NUKDOS software for treatment planning in molecular radiotherapyPeter Kletting, Sebastian Schimmel, Heribert Hänscheid, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 11, 2020
Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in <sup>177</sup>Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized TreatmentLuis David Jiménez-Franco, Gerhard Glatting, Vikas Prasad, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Nuklearmedizin. Nuclear Medicine|November 26, 2016
Treatment planning in PRRT based on simulated PET data and a PBPK model. Determination of accuracy using a PET noise modelDeni Hardiansyah, Wei Guo, Ali Asgar Attarwala, et al.
EJNMMI Research|March 27, 2016
Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling scheduleChristian Maaß, Jan Philipp Sachs, Deni Hardiansyah, et al.
Medical Physics|August 10, 2013
A fast method for rescaling voxel S values for arbitrary voxel sizes in targeted radionuclide therapy from a single Monte Carlo calculationMaría Fernández, Heribert Hänscheid, Thibault Mauxion, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 19, 2015
Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE TherapyPeter Kletting, Thomas Kull, Christian Maaß, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2010
Radioimmunotherapy with anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic modelPeter Kletting, Thomas Kull, Donald Bunjes, et al.
Scientific Reports|December 29, 2019
The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK modelNusrat J Begum, Gerhard Glatting, Hans-Jürgen Wester, et al.
Pharmaceutics|December 28, 2021
A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in MiceNouran R R Zaid, Peter Kletting, Gordon Winter, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 19, 2015
The role of patient-based treatment planning in peptide receptor radionuclide therapyDeni Hardiansyah, Christian Maass, Ali Asgar Attarwala, et al.
Zeitschrift Fur Medizinische Physik|March 21, 2015
The NUKDOS software for treatment planning in molecular radiotherapyPeter Kletting, Sebastian Schimmel, Heribert Hänscheid, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 11, 2020
Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in <sup>177</sup>Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized TreatmentLuis David Jiménez-Franco, Gerhard Glatting, Vikas Prasad, et al.
Pageof 5